Heterogeneity in Precision Oncology

Overview

Journal Camb Prism Precis Med

Publisher Cambridge University Press

Date 2024 Mar 29

PMID 38549846

Authors

Bartlomiej Tomasik

Filip Garbicz

Marcin Braun

Michal Bienkowski

Jacek Jassem

Affiliations

Soon will be listed here.

Abstract

Precision oncology is a rapidly evolving concept that holds great promise in cancer treatment. However, a cancer complexity attributed to genomic and acquired tumour heterogeneity limits treatment effectiveness and increases toxicity. These limitations refer to both systemic therapies and radiotherapy, which are two mainstays of non-invasive cancer treatment. By understanding cancer heterogeneity and utilising advanced tools to personalise treatment strategies, precision oncology has the potential to revolutionise cancer care. In this article, we review the current status of precision oncology in solid tumours, specifically focusing on the impact of tumour heterogeneity and genomic patient features on systemic therapies and radiation. We also discuss the implementation of novel tools, such as next-generation sequencing and liquid biopsies, to overcome this problem.

References

Zhou J, Wang J, Zhang X, Tang Q . New Insights Into Cancer Chronotherapies. Front Pharmacol. 2021; 12:741295. PMC: 8710512. DOI: 10.3389/fphar.2021.741295. View

Iwakawa M, Imai T, Harada Y, Ban S, Saegusa K, Sagara M . [RadGenomics project]. Nihon Igaku Hoshasen Gakkai Zasshi. 2002; 62(9):484-9. View

Scott J, Sedor G, Ellsworth P, Scarborough J, Ahmed K, Oliver D . Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol. 2021; 22(9):1221-1229. DOI: 10.1016/S1470-2045(21)00347-8. View

Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist L . Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005; 7(3):R284-90. PMC: 1143572. DOI: 10.1186/bcr993. View

Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg D, Wain J . Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004; 10(15):4939-43. DOI: 10.1158/1078-0432.CCR-04-0247. View

Nath A, Bild A . Leveraging Single-Cell Approaches in Cancer Precision Medicine. Trends Cancer. 2021; 7(4):359-372. PMC: 7969443. DOI: 10.1016/j.trecan.2021.01.007. View

Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N . Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020; 31(3):377-386. DOI: 10.1016/j.annonc.2019.11.006. View

Sjostrom M, Chang S, Fishbane N, Davicioni E, Zhao S, Hartman L . Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. J Clin Oncol. 2019; 37(35):3340-3349. PMC: 6901281. DOI: 10.1200/JCO.19.00761. View

van Tilburg C, Pfaff E, Pajtler K, Langenberg K, Fiesel P, Jones B . The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021; 11(11):2764-2779. PMC: 9414287. DOI: 10.1158/2159-8290.CD-21-0094. View

10.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

11.

Franco N, Massi M, Ieva F, Manzoni A, Paganoni A, Zunino P . Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiother Oncol. 2021; 159:241-248. PMC: 8754257. DOI: 10.1016/j.radonc.2021.03.024. View

12.

Topol E . Individualized medicine from prewomb to tomb. Cell. 2014; 157(1):241-53. PMC: 3995127. DOI: 10.1016/j.cell.2014.02.012. View

13.

Park D, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz H . A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001; 61(24):8654-8. View

14.

Flaherty K, Gray R, Chen A, Li S, Patton D, Hamilton S . The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020; 112(10):1021-1029. PMC: 7566320. DOI: 10.1093/jnci/djz245. View

15.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

16.

Citrin D . Recent Developments in Radiotherapy. N Engl J Med. 2017; 377(11):1065-1075. DOI: 10.1056/NEJMra1608986. View

17.

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

18.

Rothwell D, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E . Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019; 25(5):738-743. DOI: 10.1038/s41591-019-0380-z. View

19.

de Bono J, Ashworth A . Translating cancer research into targeted therapeutics. Nature. 2010; 467(7315):543-9. DOI: 10.1038/nature09339. View

20.

Babina I, Turner N . Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17(5):318-332. DOI: 10.1038/nrc.2017.8. View